Upcoming AWS Coverage on Envestnet

LONDON, UK / ACCESSWIRE / March 17, 2017 / Active Wall St. blog coverage looks at the headline from First Data Corp. (NYSE: FDC) as the Company announced on March 16, 2017, that it has entered into a definitive agreement to acquire Acculynk, an Atlanta-based technology Company which delivers ecommerce solutions for debit card acceptance. This transaction offers First Data access to Acculynk’s PaySecure debit routing technology and multiple other services for businesses of variable sizes across the world. Register with us now for your free membership and blog access at:

http://www.activewallst.com/register/

One of First Data’s competitors within the Business Services space, Envestnet, Inc. (NYSE: ENV), made an announcement on February 22, 2017, that it will report its results for the fourth quarter and year ended December 31, 2016, upon the finalization of its financial statements. AWS will be initiating a research report on Envestnet following its pending earnings results.

Today, AWS is promoting its blog coverage on FDC; touching on ENV. Get all of our free blog coverage and more by clicking on the link below:

http://www.activewallst.com/register/

The Debit Routing Technology

This unique technology from Acculynk enables merchants to process online debit payments through the most cost-effective available debit network, helping merchants reduce the total cost of acceptance. Additionally, The True Debit gateway via PaySecure minimizes fraud rates, expedites payment settlement, and eventually creates consumer experience with less friction. Acculynk views multiple growth prospects available through First Data client landscape from multinational corporations to sole proprietors operating online stores.

Acculynk’s Expansion Portfolio

Acculynk views this transaction as a step to streamline ecommerce and reduce transaction costs for businesses around the world. The unrivaled global scale and distribution will expand PaySecure’s footprint and offer added benefits to merchants while simplifying debit card ecommerce transactions for consumers across the world. First Data, on the other hand, will acquire Acculynk’s other product offerings, including PayGov, a government bill pay solution, and Payzur, a white-label P2P solution distributed by financial institutions for customer use.

The PIN-debt Company

Acculynk was formed in 2008 when it paid $600,000 to buy the key online PIN-debt technology from Pay By Touch Inc., which acquired the same service for $30.5 million three years back. PayByTouch specialized in biometrically authenticated point-of-sale transactions where it was developed by a startup called ATM Direct. The service relied on a unique floating PIN pad served up on a computer screen. Hence, to thwart key-loggers, the numerical arrangement on the PIN pad would vary for each instance it was invoked.

A Long-term Collaboration Induced Acquisition

On February 14, 2011, Acculynk announced that First Data, the leader in electronic commerce and payment processing, will offer online merchants PaySecure through First Data’s ecommerce payment processing platforms. PaySecure offered added security and convenience of PIN debit to the Internet with a patented, graphical PIN-pad that appears over the merchant checkout option for PIN entry. This agreement is viewed as a unification step for two complementary ventures.

First Data’s Growth Prospects

First Data has aimed at expanding through a multi-nation and multi-platform growth strategy. On October 24, 2016, First Data announced a new partnership with Alipay, to bring the solution to United States merchants. Currently, First Data serves more than 4 million merchant locations across the States. Post the announcement, on February 09, 2017, First Data partnered with KeyBank, (NYSE: KEY), one of the nation’s largest financial firms, to provide enhanced merchant services solutions to KeyBank’s commercial, business, and government clients across the nation.

This deal, subject to customary closing conditions, covers Acculynk’s other products including government bill payment offering and white-label P2P service for banks.

First Data hopes to expand its merchant services by relying on PaySecure’s connections to multiple debit networks, including Accel/Exchange, NYCE, Shazam, and First Data’s own Star system. The Company expects to leverage the link Acculynk has acquired which includes half a dozen domestic networks and three international systems to develop additional services while enabling single- and dual-message PINless transactions and the push payment services.

Stock Performance

On Thursday, March 16, 2017, the stock closed the trading session at $16.15, rising 1.51% from its previous closing price of $15.91. A total volume of 4.56 million shares have exchanged hands, which was higher than the 3-month average volume of 3.08 million shares. First Data’s stock price surged 10.47% in the last three months, 16.02% in the past six months, and 24.52% in the previous twelve months. Furthermore, on a year to date basis, the stock rallied 13.81%. Shares of the company have a PE ratio of 35.65.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 457547

Upcoming AWS Coverage on Burlington Stores Post-Earnings Results

LONDON, UK / ACCESSWIRE / March 17, 2017 / Active Wall St. announces its post-earnings coverage on Costco Wholesale Corp. (NASDAQ: COST). The Company reported its second quarter fiscal 2017 operating results on March 02, 2017. The Warehouse club retailer’s Comparable Sales increased 3%. Register with us now for your free membership at:

http://www.activewallst.com/register/

One of Costco Wholesale’s competitors within the Discount, Variety Stores space, Burlington Stores, Inc. (NYSE: BURL), reported on March 02, 2017, results for Q4 and fiscal year ended January 28, 2017. AWS will be initiating a research report on Burlington Stores in the coming days.

Today, AWS is promoting its earnings coverage on COST; touching on BURL. Get our free coverage by signing up to:

http://www.activewallst.com/register/

Earnings Reviewed

For the twelve weeks ended February 12, 2017, Costco’s net sales increased 6% to $29.13 billion from $27.57 billion last year. The Company’s net sales lagged behind analysts’ consensus of $29.85 billion. On a reported basis, comparable sales (Comp) were up 3% for Q2 FY17 and excluding gas and FX, they still remained up 3%. For the reported quarter, the plus 3% reported comp was a combination of an average transaction increase of a little over 1%, and an average shopping frequency increase of 2%. The Company’s net sales for H1 2017 grew 4%, to $56.60 billion from $54.19 billion last year.

For the four-week reporting month of February, ended February 26, 2017, the Company reported net sales of $8.92 billion, an increase of 8% from $8.28 billion during the similar four-week period last year.

For Q2 FY17, Costco reported net income of $515 million, or $1.17 per diluted share, compared to $546 million, or $1.24 per diluted share, in the year ago comparable period. The Company’s earnings numbers came in below market estimates of $1.36 per share. Costco’s net income for H1 2017 was $1.06 billion, or $2.41 per diluted share, compared to $1.03 billion, or $2.32 per diluted share, in H1 2016.

Membership Details

During Q2 FY17, Costco’s membership fees totaled $636 million, up 5% on a y-o-y basis. The Company continued to enjoy strong renewal rates, coming in a little over 90% in the US and Canada, and 87.7% worldwide on a fully captured basis.

Costco’ members at the end of Q2 FY17, primary Gold Star came in at 37.5 million, up from 12 weeks earlier at 37.1 million. Primary business totaled 7.4 million up from 7.3 million 12 weeks earlier. Business add-on members were 3.4 million at the end of the reported quarter, down from 3.5 million. Overall, the Company had 48.3 million total accounts compared to 47.9 million the earlier fiscal quarter.

At the end of Q2 FY17, Costco reported 88.1 million total card holders, up from 87.3 million 12 weeks earlier. As of Q2 end, the Company’s paid Executive Memberships stood at 17.9 million which is an increase of about 200,000 from 12 weeks earlier, or about 17,000 additional per week. Executive members represented a little over one-third of its member base, and about two-thirds of our sales.

Costco announced that, effective June 01, 2017; it will increase annual membership fees by $5 for US and Canada Goldstar (individual), Business, and Business add-on members (“Primary” Members). With this increase, all US and Canada Goldstar, Business and Business add-on members will pay an annual fee of $60. Also effective June 01, annual fees for Executive Memberships in the US and Canada will increase from $110 to $120 (Primary membership of $60, plus the Executive upgrade of $60), and the maximum annual 2% reward associated with the Executive Membership will increase from $750 to $1,000. The fee increases will impact around 35 million members, roughly half of them Executive Members.

Store Update

Costco currently operates 728 warehouses, including 508 in the United States and Puerto Rico, 94 in Canada, 37 in Mexico, 28 in the United Kingdom, 25 in Japan, 13 in Korea, 13 in Taiwan, 8 in Australia, and 2 in Spain. Costco also operates electronic commerce web sites in the US, Canada, the United Kingdom, Mexico, Korea, and Taiwan.

In Q2 FY17, the Company opened four new locations. Those included Costco’s 13th unit in each of Korea and Taiwan, as well as two new locations in Florida, in the Tampa area. For all of FY17, the Company has plans of 29 net new locations, so 17 additional openings during the third and fourth quarters of FY17 are planned. Of the 29 for the year, 14 in the US, 8 in Canada, and 1 each in Japan, Korea, Taiwan, Mexico, and Australia, as well as its first openings in France and Iceland, most likely in mid to late May.

Stock Performance

On Thursday, March 16, 2017, the stock closed the trading session at $167.06, slightly up 0.31% from its previous closing price of $166.54. A total volume of 2.73 million shares have exchanged hands, which was higher than the 3-month average volume of 2.33 million shares. Costco Wholesale’s stock price advanced 4.84% in the last three months, 11.50% in the past six months, and 9.68% in the previous twelve months. Furthermore, since the start of the year, shares of the Company have gained 4.62%. The stock is trading at a PE ratio of 30.85 and has a dividend yield of 1.08%.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 457543

Thanks to buttercast, Podcast Producers will No Longer Have to Pay a Great Deal of Money for Expensive Software and
Equipment

LOS ANGELES, CA / ACCESSWIRE / March 17, 2017 / Turgay Birand, Co-Founder and CEO of buttercast, is pleased to announce the launch of a new and innovative online platform that will revolutionize the podcasting industry.

To learn more about buttercast and its many features that will make it easy to publish amazing-sounding podcasts, please check out https://www.buttercast.com at any time.

As Birand noted, buttercast, which is a software as a service offering, has one key mission: to make creating terrific podcasts easier for everybody. Thanks to the newly-launched service, podcast producers will no longer need to invest in expensive software packages and equipment.

In order to make the podcast production and listening experiences better for creators and audiences, buttercast employs advanced audio processing algorithms that enhance the sound quality of podcast episodes hosted on their platform.

“It will also help ease some time-consuming editing processes podcasters need to endure, such as cutting lengthy silences and cleaning up background noise, which are performed automatically with cutting edge processing algorithms in the cloud,” Birand said.

A podcast named after the product has already been released on iTunes, Google Play and Stitcher, which Birand said will make podcasters’ lives easier by providing useful tips from the perspective of a newcomer. The buttercast website also hosts a blog that offers tips and tricks geared towards helping podcasters on their path to success.

As Birand noted, podcasting has been an extremely fast growing space with 21 percent net growth in 2016, and close to 20 percent over each of the preceding five years. Every year, tens of thousands of new podcasters are entering the space, making podcasting one of the fastest growing online media channels in the world.

“The podcast is the new radio, and it’s here not only to stay but take over the world of aural broadcasting. The year to year growth numbers are simply astounding, and we’re proud to become a part of this paradigm shift with our new offering,” Birand said.

Podcasters can get their careers started with buttercast for free until their podcast grows to above five episodes. After that, a podcast with unlimited episodes only costs $10 per month, making buttercast the most cost-effective hosting platform out there that also offers built in audio enhancement features.

In the near future, Birand and the rest of the team behind buttercast plans to add even more audio enhancing capabilities, such as professional grade audio equalizers and algorithms such as DeEsser and Smart Noise Reducer.

About buttercast:

Buttercast is a podcasting platform with a mission to make publishing amazing sounding podcasts easier for everyone. No longer will podcast producers need to invest in expensive equipment and software packages. By employing advanced audio processing algorithms, Buttercast automatically enhances the sound quality of podcast episodes hosted on their platform. For more information, please visit https://www.buttercast.com.

Contact:

Turgay Birand

turgay@buttercast.com
+1 302 319 2019

SOURCE: Buttercast

ReleaseID: 457545

Conference Call Scheduled for Today at 8:30 a.m. Eastern Time

BEDMINSTER, NJ / ACCESSWIRE / March 17, 2017 / CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today provided its corporate update for the fourth quarter and full year ended December 31, 2016. CorMedix will host a conference call today, March 17, 2017, at 8:30 a.m. Eastern Time to discuss the Company’s recent corporate developments and financial results.

Recent Corporate and Clinical Highlights:

Surpassed enrollment midpoint in pivotal Phase 3 “LOCK-IT 100” study of Neutrolin® in hemodialysis patients; On track to complete enrollment as planned
Enhanced the senior leadership team with appointment of Robert W. Cook as Chief Financial Officer; Judith R. Abrams, M.D., as Chief Medical Officer; and John L. (Jack) Armstrong as Executive Vice President of Technical Operations and Head of Human Resources
Formally started the preclinical work with the POETIC group to evaluate CRMD-005 in combination with vincristine to treat pediatric cancers

Anticipated Milestones:

Complete enrollment in LOCK-IT 100 study by year-end 2017; Report top-line data in the second half of 2018
Anticipate the commencement of the second Phase 3 “LOCK-IT 200” study in oncology patients by year-end 2017
Advance preclinical studies of taurolidine-based cancer therapy under POETIC collaboration

Khoso Baluch, Chief Executive Officer of CorMedix, said, “The fourth quarter of 2016 and early 2017 are marked by significant clinical execution for our lead candidate Neutrolin for the prevention of central venous catheter-related bloodstream infections. Through our successful efforts to overcome certain challenges and accelerate enrollment of hemodialysis patients into our Phase 3 LOCK-IT 100 study in the U.S., we are pleased to report that we have surpassed the midpoint of study enrollment. We are currently enrolling patients at greater than 50% of our target clinical trial sites and we continue to activate and enroll patients regularly at additional sites. Importantly, we remain on track to complete study enrollment as planned by year-end 2017. Our core focus remains on securing FDA approval and commercializing Neutrolin in the U.S., and we believe we are well on our way toward achieving that goal.”

Mr. Baluch continued, “A critical component of our success will be the senior leadership we have in place to ensure our programs run efficiently. Recently, we were pleased to add Robert Cook, Dr. Judith Abrams, and Jack Armstrong to our management team, bringing decades of clinical, fundraising, strategic and operational expertise that will benefit CorMedix as we advance Neutrolin and explore additional opportunities to build value for our taurolidine-based pipeline.”

“Looking beyond Neutrolin, we are excited to work with the leading cancer centers that comprise the POETIC group to pursue development of a novel taurolidine-based combination therapy for the treatment of pediatric cancers, including neuroblastoma and osteosarcoma. We look forward to the in vitro and in vivo studies to explore the potential of this combination therapy, and its potential advancement to human clinical studies in the future.”

For the full year 2016, the Company recorded a net loss of $24.6 million, or $0.65 per share, compared with a net loss of $18.2 million, or $0.58 per share, during 2015. The 2016 net loss was driven by a Loss from Operations of $24.8 million, which resulted from a significant increase in clinical trial expenses, CMC and other Neutrolin-related development expenses, and new product development expenses, partially offset by a decline in SG&A expenses. Cash used in operations during 2016 amounted to $22.2 million, a 78% increase over 2015’s cash use of $12.5 million, primarily due to the ramp up of the LOCK IT 100 clinical trial and other R&D expenses. $6.2 million of the cash use was funded via the Company’s “At the Market” program, with the balance drawn from existing cash on hand. As of December 31, 2016, the Company has availability of an additional $4.1 million via the ATM program.

Cash on hand as of December 31, 2016, was $20.2 million, including short term investments, compared with $35.4 million as of December 31, 2015. Based on the Company’s cash resources at year-end and the expected cost of the Phase 3 clinical trial in hemodialysis catheters in the U.S., the Company expects that its existing cash and short-term investments will be insufficient to fund operations through 2017. The Company is exploring various funding opportunities while it aims to optimize its cash.

Mr. Baluch concluded, “We are committed to unlocking significant long term value for our shareholders by successfully completing our Phase 3 studies and launching Neutrolin into a broad and sizable U.S. market upon potential approval. We look forward to continued clinical execution over the coming months.”

Conference Call Information:

Please call five minutes before the conference call is scheduled to begin.
Dial-In (Toll Free): 877-407-8031
International Dial-In: 201-689-8031

The live audio webcast will be accessible via the Events section of the CorMedix website.

A replay of the teleconference will be available until 11:59 p.m. on March 24, 2017.
Replay Number: 877-481-4010
Replay International: 919-882-2331
Conference ID: 10273

About CorMedix Inc.

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease. The Company is focused on developing its lead product, Neutrolin®, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. Such infections cost the U.S. healthcare system approximately $6 billion annually and contribute significantly to increased morbidity and mortality. Neutrolin is currently in a Phase 3 clinical study in patients undergoing chronic hemodialysis via a central venous catheter. The Company is planning to conduct its second Phase 3 study in patients with cancer receiving IV parenteral nutrition, chemotherapy and hydration via a chronic central venous catheter, subject to sufficient resources. If successful, the two pivotal studies may be submitted to the FDA for potential approval for both patient populations. Neutrolin has FDA Fast Track status and is designated as a Qualified Infectious Disease Product, contributing to potentially accelerated FDA review and up to 10 years of market exclusivity upon potential U.S. approval. It is already a CE Marked product in Europe and other territories. For more information, visit: www.cormedix.com.

For Investors & Media:

Tiberend Strategic Advisors, Inc.

Joshua Drumm, Ph.D.: jdrumm@tiberend.com; (212) 375-2664
Janine McCargo: jmccargo@tiberend.com; (646) 604-5150

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or CorMedix’s prospects, future financial position, financing plans, future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including: the cost, timing and results of the planned and ongoing Phase 3 trials for Neutrolin® in the U.S. and the resources needed to commence and complete those trials; the risks and uncertainties associated with CorMedix’s ability to manage its limited cash resources; CorMedix’s ability to obtain financing to support its research and development and clinical activities and operations; obtaining regulatory approvals to conduct clinical trials and to commercialize CorMedix’s product candidates, including the planned Phase 3 trial of Neutrolin in oncology patients and the marketing of Neutrolin in countries other than Europe; the outcome of clinical trials of CorMedix’s product candidates and whether they demonstrate these candidates’ safety and effectiveness; the risks associated with the launch of Neutrolin in new markets; CorMedix’s ability to enter into, execute upon and maintain collaborations with third parties for its development and marketing programs; CorMedix’s dependence on its collaborations and its license relationships; CorMedix’s ability to maintain its listing on the NYSE MKT; achieving milestones under CorMedix’s collaborations; obtaining additional financing to support CorMedix’s research and development and clinical activities and operations; CorMedix’s dependence on preclinical and clinical investigators, preclinical and clinical research organizations, manufacturers, sales and marketing organizations, and consultants; and protecting the intellectual property developed by or licensed to CorMedix. These and other risks are described in greater detail in CorMedix’s filings with the SEC, copies of which are available free of charge at the SEC’s website at www.sec.gov or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

SOURCE: CorMedix Inc.

ReleaseID: 457513

VANCOUVER, BC / ACCESSWIRE / March 17, 2017 / After three straight years of declining prices, spot gold gained value in 2016 and is holding an upward path again so far in 2017, lending to the idea that the low of $1,045 late in 2015 indeed may have been a rotation out of a downtrend for the precious yellow metal. Savvy investors know that the best way to make money is at the bottom of a cycle. If you’re looking to juniors with a lower risk profile, turning to companies with a near-term cash flow plan to fund other long-term project development is a good way to go. That means companies like MX Gold (TSX-V: MXL)(OTCQX: MXLGF), who just acquired a near-term producer in Mexico for a song should generate revenue in the not-too-distant future.

For Vancouver-based MX Gold, near-term, low-cost production can be achieved through tailings projects that failed to use modern technologies to process ore, ultimately leaving dollar bills in the scrap pile. Mine tailings are the part of the rock leftover after the economic mineral concentrates are removed from unearthed ore. The quality of the tailings can vary greatly depending on what degree of mechanical or chemical (or both) processes were employed to remove the gold and other minerals the first time around.

In many cases, perhaps even the majority of mining operations in the past two hundred years worldwide, inefficient methods were used relative to today’s techniques, taking only the gold of the highest grade that was easily extracted. After all, when gold was only fetching $20 an ounce, as it was 100 years ago, artisanal miners didn’t even have the technology available to economically collect all the gold in the ore, so it was sent to the tailings pile, dam or dump.

That means there’s a lot of good gold still to be had if you’re looking in the right places; it just needs to be reprocessed with modern technology. In many cases, the tailings pile is not small, it can cover hundreds of thousands of tonnes of material. The process is similar to conventional approaches to proving reserves, conducting studies to determine the best extraction method, sampling, assays, etc., only there is not the extensive resources spent on the initial discovery, leading a much quicker time to production.

MX Gold has a project portfolio focused on mining friendly jurisdictions with infrastructure intact, including paved roads, electricity, rail, skilled workers, etc. The company’s flagship project is the high-grade Willa gold and copper project located 12 kilometers south of Silverton, British Columbia. Two years ago, the company acquired the Willa gold/copper project and the Max molybdenum mine and mill complex, comprised of the property and a 1,000 ton per day mill and tailings facility with all requisite permits in place. The projects have since been consolidated into the “WillaMax” project.

There is about 2,600 meters of underground workings, nearly 600 drill holes and more than $18 million has been spent in the past four decades exploring the Willa property. A NI 43-101 report in 2012 showed 42,024 ounces of gold Measured, 126,351 ounces gold Indicate and 26,760 ounces Inferred from the West Zone at a 3.0 g/t cut-off, without consideration for the North and East Zones.

At Max, $80 million has been spent on mine development and expansion in the last 10 years. Production began in 2007, but was slowed and halted due to stubbornly low molybdenum prices. As prices cooperate, MX Gold could expand throughput, which would lower costs, and re-start production while seeking to further delineate and expand resources across the complete WillaMax project.

Perhaps even more immediately intriguing is the $2.5 million MX Gold spent for 50% participating ownership interest and a 45% net profit participating interest in the Magistral Del Oro tailings project in Santa Maria Del Oro, Durango, Mexico. MX Gold acquired its interest late in 2016 through a partnership with Gracepoint Mining, a subsidiary of Firma Holdings Corp. (FRMA). Adding to the Durango prospect, MX Gold followed that up last month with a binding option agreement with American Metal Mining S.A. de C.V., whereby for $1.525 million it earned a 50% stake in the company holding a past producing gold smelter, three acres of surrounding land and various permits and equipment associated with the property (truck scale, metallurgical lab, crushing circuit, etc.).

MX Gold has already completed the $2.5 million payment and made payments of $650,000 towards the smelter and assets.

In aggregate, MX Gold for less than $4 million has substantial ownership in Durango of a (non-NI 43-101 compliant) reserve estimate for the tailings of 1.215 million tonnes averaging 2.06 g/t gold. That’s equal to roughly 79,000 ounces. At an 82% recovery rate – as confirmed by independent mining firm Kappes Cassiday & Associates – that’s more than $75.0 million in gold.

They also have half ownership of a 500 tonne-per-day dynamic cyanide countercurrent system plant that cost $4.5 million to build, which was completed four years ago. Generally speaking, countercurrent washing circuits are more expensive that traditional systems, but more effective than filtration systems, improving yield and saving resources, while lessening the environmental impact. MX Gold believes the plant can be operating in 4-6 months.

The fully permitted smelter, built to receive and process high-grade ores and concentrates, was completed in 2014 and has a capacity of 50 tonnes per day. The smelter, which was a project of Durango State Senator Rosa Isela De La Rocha, was designed to provide jobs and revenue for the Durango mining community by processing material from miners all across Durango and surrounding states. The initiative of the Senator speaks to the commitment of Durango to foster mining operations.

Gold looks to be turning the corner and slowly making its way back in the direction of 2011 record highs above $1,900 per ounce. The path will not be linear, it will take time and experience dramatic swings, just as gold always does. Depressed prices in slow economies present opportunities, though, and that is what MX Gold appears to have presciently aligned itself to do by capitalizing with the acquisitions in Mexico at very favorable prices. If the company can achieve near-term production at low costs from the tailings, it’s a strong hedge to cope with any gold fluctuations in the coming years while providing cash flow for the large WillaMax property.

Legal Disclaimer/Disclosure: This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this Report should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. We make no guarantee, representation or warranty and accept no responsibility or liability as to its accuracy or completeness. Baystreet.ca assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this Report.

Contact:

Aaron Bodnar aaron@baystreet.ca

SOURCE: Baystreet Media Corp.

ReleaseID: 457533

VANCOUVER, BC / ACCESSWIRE / March 17, 2017 / There’s nothing more potentially rewarding right now than a visionary biotech company poised for explosive gains on the basis of a ground-breaking drug, medical device or procedure.

Large-cap or small-cap, this is the definitive year of biotech, and these five picks are all set for big things in 2017—with momentous catalysts that promise massive future earnings if you get in at the right time.

Our Top 5 Biotech Picks Right Now:

#1 Amgen (AMGN)

Amgen is the top biotech company in the U.S., with a market cap of $132.41 billion–and it’s releasing the results of a key clinical study on Friday, 17 March. The study is for LDL cholesterol-buster Repatha, and it’s expected to show the ability to reduce heart attacks, strokes and cardiovascular disease.

Preliminary data from the study has already been released.

Repatha already has approval to reduce bad cholesterol, and in doing so it is competing against Praluent, developed by Regeneron and Sanofi. This could be explosive, but it’s not without its controversy. So far though, it’s been good news for Amgen because a judge has ruled that Praluent infringes on Amgen’s patents for Repatha. Praluent is appealing, but for now there’s an injunction on the drug.

Repatha (and Praluent) block an enzyme that degrades receptors responsible for removing bad cholesterol from the blood stream. This is a potentially $5-billion global market over the next five years, and in the U.S. alone we’re looking at a market of some 5 million patients potentially.

Amgen’s shares have jumped 23.8% this year so far, putting it at a higher share price increase than its peers in the industry.

So with uptake of Repatha already approved by the FDA in the summer of 2015, and the full study for wider use set to be released with positive results on Friday, what’s been a great year so far for Amgen is about to get even better.

#2 CVR Medical (TSX:CVM.V ; OTC:CRRVF)

CVR Medical’s Carotid Stenotic Scan (CSS) is a potentially ground-breaking innovation designed to detect Ischemia—the leading indicator of stroke—in only 2 minutes, and for a price that makes pre-stroke intervention affordable and accessible for the first time ever.

This little-known, visionary biotech company is gearing up to release its new medical device soon, with preliminary trial results due any day, and full clinical results to follow 4-8 weeks after that. That’s when we expect the breakout.

This device fills an urgent medical market gap. It could help save six million lives a year—or a life every 4 minutes.

Globally, every year 15 million people suffer a stroke. In the U.S. alone, nearly 800,000 people suffer from a stroke annually. One out of every 20 deaths in America is caused by stroke, and until now, there has been no cost-effective way to screen for the leading indicator of Ischemic strokes, which cost the U.S. government alone over 30 billion dollars a year in healthcare expenses.

The patented technology is positioned to own this huge market segment. A CSS unit costs roughly $49,000, and over 230,000 medical facilities in the U.S. alone could potentially want the device. Globally the demand could be huge.

The visionary team has invested $23 million in development, and the best part is that they’ve done it quietly and stayed off the radar. This is a huge deal for potential investors who can get in on the ground floor of one of the biggest potential new medical device breakouts in a decade.

Once the clinical results are in, the next step is FDA clearance, and then we expect this device to explode on the market.

#3 Cara Therapeutics Inc. (CARA)

This $425.39M market cap company is on the verge of a breakout in the multi-billion-dollar painkiller market, which was at $11 billion in 2014 and building at a steady pace since.

Pain relief is one of the biggest and broadest ongoing medical challenges of our time, and it’s a problem that has led to unprecedented opiate addiction. An estimated 26.4 million to 36 million people abuse opioids worldwide, according to the U.S. government’s National Institute on Drug Abuse. In the U.S. alone, an estimated 2.4 million people suffer from substance use disorders related to opioid pain relievers. In 2015, over 47,000 Americans died from drug overdoses—61% of the cases involving opioids. An estimated 47,000 Americans are addicted to heroin.

Cara is targeting opioids—the most heavily abused class of drugs in the country—with a new drug that is designed to avoid the central nervous system, stopping pain but not acting like an addictive narcotic. Right now the drug is specifically targeting 3 million Americans who suffer from kidney disease-related itching.

The company is developing the abuse-deterrent CR845 and expects to reveal data by the end of March from a trial that will pave the way for a second trial to supports its FDA application. The specific target is just the beginning of what could be a huge long-term winner.

If this is successful, expect a breakout—and investors are already on to the possibility. Cara has seen its stock jump over 200% in the past year.

#4 Clovis Oncology Inc. (CLVS)

With a market cap of $3.21 billion, Clovis is a monster in the biotech market, but it’s also trading like a monster, with stock prices exploding in price and volume this year.

Clovis acquires, develops and commercializing anti-cancer agents primarily in the U.S. and Europe, but also elsewhere globally.

Clovis has a PARP inhibitor called Rucaparib, which was recently approved by the FDA. It’s also got two other product candidates: 1) Rociletinib, an oral epidermal growth factor receptor, mutant-selective covalent inhibitor under review in both the U.S. and Europe, for the treatment of non-small cell lung cancer; 2) Lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors.

But it’s Rucaparib—an oral inhibitor for the treatment of ovarian cancer—that is in the advanced stage of clinical development, and what everyone is watching right now.

The biggest push came last week with positive trial results from AstraZeneca’s (AZN) ovarian cancer drug trial, which means good news for Clovis’ drug trial. So much so in fact that it prompted Goldman Sachs to raise its price target on Clovis from $44 to a whopping $75. But that’s only in the short term—analysts see $85 as the next target.

Clovis has insider ownership of 17.40% and institutional ownership of 88.48%.

#5 Mylan N.V. (MYL)

Mylan is the largest supplier of cancer medicines by volume in the U.S., with a $22.7 billion market cap.

This generic drugmaker has had a tough year because of a legal battle with Roche, but that was settled this week, paving the way for the launch of a generic version of a top-selling breast cancer drug, Herceptin in major markets. Roche’s Herceptin generated sales of $6.7 billion in 2016 alone, so the generic version by Mylan is set to explode onto this market and drive future growth.

For Mylan, the settlement of the patent dispute with Roche means it can secure the global license for its rival version, which is generically known as trastuzumab. Mylan is already selling this generic version in 14 emerging markets, and it’s been submitted for approval in Europe and the U.S.

This is a huge catalyst that should be on any sophisticated investor radar in the biotech field.

And it’s not the only catalyst. On 13 March, Mylan launched Exemestane Tablets in the U.S. after receiving final FDA approval—a generic version of Pfizer’s Aromasin® Tablets, for treatment of certain types of breast cancer in women after menopause. This adds nicely to the already significant oncology franchise, and Exemestane is expected to see $100 million in U.S. sales for 2017.

If you’ve bought shares in any of these stocks last year, you’ll be happy today because recent highs have been cosmic, and coming highs even more explosive.

A few more biotech gems that make our honorable mentions list—and they’re cheaper than ever before:

– Biogen (BIIB)

This major player’s stocks are down 30% from its high a couple of years ago, but there’s plenty of reason to be bullish.

– Celgene (CELG)

There’s quite a bit of upside to the large-cap player, which is considered a fairly low risk and could yield some ‘blockbuster’ drugs.

– AEterna Zentaris Inc. (AEZ)

AEterna just finished the clinical phase of their development of Zoptrex™

– Bellus Health Inc. (BLU)

This company has seen nice gains over the past five sessions.

– Trillium Therapeutics Inc. (TR)

This company has plenty of catalysts, and Janus Capital Management LLC just raised its position in shares.

Legal Disclaimer/Disclosure: This piece is an advertorial and has been paid for. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this Report should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. We make no guarantee, representation or warranty and accept no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of Baystreet.ca only and are subject to change without notice. Baystreet.ca assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this Report.

Contact:

Aaron Bodnar aaron@baystreet.ca

SOURCE: Baystreet Media Corp.

ReleaseID: 457532

SPRINGDALE, AR / ACCESSWIRE / March 17, 2017 / Advanced Environmental Recycling Technologies, Inc. (OTCQB:AERT) announced today that net sales for the year ended December 31, 2016 were $85.3 million, up 3.2% from $82.7 million for the previous year. Net sales for the fourth quarter of 2016 were $18.7 million, up $1.6 million or 9.4% from $17.1 million in the fourth quarter of 2015.

Commenting on the results, Tim Morrison, CEO of AERT noted, “AERT continues to build momentum. In 2016 our associates expanded our distribution relationships and focused on achieving operational efficiencies, resulting in measurable growth in both top and bottom lines. Those efforts will continue into 2017 as we build upon those successes and increase our focus on new product introduction. We have commenced selling our new products which were recently displayed at the International Builders Show in Orlando. We are especially excited to introduce our CoolDeck™ line of products which uniquely provide a more comfortable user experience. Early indications are that our customers are as excited as we are about our new products.”

Gross Margin increased $5.3 million to $22.4 million for 2016 while the fourth quarter gross margin increased to $4.5 million from $3.8 million in the fourth quarter of 2015.

AERT’s net income for 2016 was $2.2 million as compared to the 2015 net loss of $0.9 million.

The Company has filed its 2016 Form 10-K with the SEC and will host a conference call and webcast on Friday, March 17, 2017, beginning at 11:00 am (EDT), 10:00 am (CDT) to discuss the results. Listeners may participate in a question and answer session toward the end of the webcast by calling (866) 682-6100. To listen via internet visit http://aert.com/investor-relations.

About Advanced Environmental Recycling Technologies, Inc.

Since 1989, AERT (OTCQB: AERT) has pioneered the use of recycled polyethylene plastic in the manufacture of composite building materials. With its constantly evolving portfolio of patented and proprietary recycling technologies, AERT has been widely recognized as a leader in resource conservation innovation and received the EPA Award for Environmental Excellence for its process of converting scrap plastic to composite outdoor decking. AERT converts reclaimed plastic and wood fiber waste into quality outdoor decking systems, fence systems, and door and window components. The Company is the exclusive manufacturer of ChoiceDek® decking, which is available in multiple colors and is sold in Lowe’s Home Improvement stores nationwide. See http://www.choicedek.com for more information. AERT’s MoistureShield® decking program is expanding and products are now available throughout the U.S. See http://www.moistureshield.com for product information or to find a regional distributor or dealer. AERT’s primary manufacturing facility is located in Springdale, Arkansas, and the company also operates recycling facilities in Lowell, Arkansas and Watts, Oklahoma.

Advanced Environmental Recycling Technologies, Inc. (OTCQB: AERT) trades on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies. Companies are current in their reporting and undergo an annual verification and management certification process. Investors can access real-time quotes and market information for the company on http://www.otcmarkets.com. For more information on the Company, visit http://www.aert.com. Sign up to receive investor information, including press releases, via email by visiting http://aert.com/contact-us/.

Certain statements in this news release regarding projected results of operations or projected results of financial plans or future strategies and initiatives including, but not limited to, projections of revenue, projections of profitability, any and all future expectations, and plans for future activities may and should be regarded as ”forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve, among other things, known and unknown risks, uncertainties and other factors that may cause AERT, Inc.’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect management’s current judgment, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, or other future performance suggested herein. Some important factors (but not necessarily all factors) that could affect the sales volumes, growth strategies, future profitability and operating results, or that otherwise could cause actual results to differ materially from those expressed in any forward-looking statement include the following: market, political or other forces affecting the pricing and availability of plastics and other raw materials; accidents or other unscheduled shutdowns affecting us, our suppliers’ or our customers’ plants, machinery, or equipment; competition from products and services offered by other enterprises; our ability to refinance short-term indebtedness; state and federal environmental, economic, safety and other policies and regulations, any changes therein, and any legal or regulatory delays or other factors beyond our control; execution of planned capital projects; weather conditions affecting our operations or the areas in which our products are marketed; adverse rulings, judgments, or settlements in litigation or other legal matters.

The foregoing listing of risks and uncertainties is not exclusive. For a more detailed discussion of some, but not all, of the risks and uncertainties that may affect AERT, Inc., see AERT, Inc.’s filing with the Securities and Exchange Commission, including its Annual Report on Form 10-K, for the fiscal year ended December 31, 2016. AERT, Inc. undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, change in strategy, or otherwise.

CONTACT: For AERT

Sarah Pore
479-203-5084
www.aert.com/investor-relations

SOURCE:Advanced Environmental Recycling Technologies, Inc.

ReleaseID: 457552

TORONTO, ON / ACCESSWIRE / March 17, 2017 / Canadian Silver Hunter Inc. (TSXV: AGH.H) (“CSH” or the “Company”). Further to the press release dated March 16, 2017, CSH is pleased to announce that First Cobalt Corp. has secured an option to acquire 100 percent of the historic Keeley-Frontier silver-cobalt mine in Northern Ontario, as per the First Cobalt press release of March 16, 2017.

CSH now acknowledges their relationship with First Cobalt Corp., as well as First Cobalt’s participation in the Keeley and Frontier mines project.

About Canadian Silver Hunter Inc.

CSH is a Canadian exploration company focused on the exploration of silver-cobalt deposits on its flagship South Lorrain Project (formerly the Keeley Frontier Project). The South Lorrain Project is located within the historic South Lorrain Silver Camp, which along with the historic Cobalt and Gowganda silver camps is part of a world class cobalt-silver district in the Abitibi Greenstone Belt between Temagami and Kirkland Lake, in northeastern Ontario.

For further information please contact:

Canadian Silver Hunter Inc.
Jeffrey Hunter
President and CEO
(416) 707 4230
info@cshi.ca
www.canadiansilverhunter.ca

CAUTIONARY STATEMENT: Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This release includes certain “forward-looking statements”. These statements are based on information currently available to the Company and the Company provides no assurance that actual results will meet management’s expectations. Forward-looking statements include, or may be based upon, estimates, forecasts and statements as to management’s expectations with respect to, among other things, the timing of the Company’s exploration, development and business plans, strategic acquisitions, the focus of the Company in the future, progress in and success of development of the Company’s mineral properties, and the Company’s performance, business prospects and opportunities. Forward-looking statements may be identified by such terms as “believes”, “anticipates”, “expects”, “estimates”, “may”, “could”, “would”, “will”, or “plan”. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results relating to, among other things, outcomes of acquisitions or other corporate transactions, exploration or development on the Company’s mineral properties, and the Company’s financial condition and prospects, could differ materially from those currently anticipated in such statements for many reasons such as: changes in general economic conditions and conditions in the financial markets; changes in demand and prices for minerals; litigation, legislative, environmental and other judicial, regulatory, political and competitive developments; operational difficulties encountered in connection with the activities of the Company; and other matters discussed in this release. This list is not exhaustive of the factors that may affect any of the Company’s forward-looking statements. These and other factors should be considered carefully, and readers should not place undue reliance on the Company’s forward-looking statements. The Company does not undertake to update any forward-looking statements that may be made from time to time by the Company or on its behalf, except in accordance with applicable securities laws.

SOURCE: Canadian Silver Hunter Inc.

ReleaseID: 457553